Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03925727 · ClinicalTrials.gov registry record · Phase 3
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
A Phase 3 study, sponsored by Mimetogen Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
NCT03925727 is a Phase 3 study that has completed, run by Mimetogen Pharmaceuticals USA. The registered enrollment target is 623 participants.
The verdict
NCT03925727, a Phase 3 study, has completed, sponsored by Mimetogen Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
Interventions
- OTHER Placebo
- DRUG Tavilermide ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2020-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03925727
The ClinicalTrials.gov registry entry for NCT03925727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mimetogen Pharmaceuticals USA, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03925727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03925727 about?
NCT03925727 is a clinical study titled "Tavilermide Ophthalmic Solution for the Treatment of Dry Eye". The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
What is the current status of trial NCT03925727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2019-03-28. Estimated completion is 2020-06-11.
What interventions are being tested in trial NCT03925727?
The interventions under investigation include: Placebo (OTHER), Tavilermide ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT03925727?
This trial is sponsored by Mimetogen Pharmaceuticals USA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.